Get all premium features to the best stock analysis tool

INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript

INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript

Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595

Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce time to market

Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO:

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published in the peer-reviewed journal Cytotherapy. One of the lead authors of the paper was INmune Bio's lead scientist for CORDStrom™ R&D, Dr Nikita M. Patel, M.Sci.,Ph.D.